Stop the Press: Is this MS? Primary Care’s Role in Recognizing and Coordinating Care for Patients with Multiple Sclerosis


Release date: March 2, 2023
Expiration date: March 2, 2024
The estimated time to complete the activity is 60 minutes.

Provider Statement

This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education.

Support Statement

This activity is supported by independent educational grants from Genentech, Jazz Pharmaceuticals, and Novartis Pharmaceuticals Corporation.

Target Audience

Physicians, advanced practice clinicians, nursing professionals, and pharmacists who practice in the primary care community and who care for patients living with MS.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Differentiate the signs and symptoms of MS versus those more indicative of other acute or chronic conditions
  • Identify diagnoses that mimic MS and strategies for an effective differential diagnosis
  • Examine recent research delineating the efficacy of early initiation of treatment with current and emerging MS disease modifying therapies along with expected side effects
  • Differentiate between presentations most suggestive of relapses and pseudorelapses in order to facilitate initiation of appropriate interventions

Mitzi Joi Williams, MD
Founder and CEO
Joi Life Wellness Group, LLC


In support of improving patient care, this activity has been planned and implemented by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

This activity was planned by and for the health care team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Credit Designation

The CMSC designates this enduring activity for a maximum of 1.00AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The CMSC designates this activity for a maximum of 1.00 NCPD credit (1.00 in the area of pharmacology).

This knowledge-based activity, UAN: JA4008165-9999-23-006-H01-P, qualifies for 1.00 contact hours (0.10 CEUs) of continuing pharmacy education credit.

All other health care professionals completing this course will be issued a statement of participation.

How to Participate in this Activity and Obtain CE Credit

There are no fees for participating and receiving credit for this activity. During the period that the activity is available for credit, participants must:

1) Read the CE information
2) Complete the pretest
3) View the video and study the educational activity
4) Complete the posttest and the evaluation form

A score of 75% correct must be achieved on the posttest to successfully complete the activity. If you do not receive a passing score, you will receive a message notifying you that you did not pass the posttest. You may retake the posttest until successful. Following the posttest and evaluation form your certificate will be made available immediately.


Faculty Disclosures
Mitzi Joi Williams, MD

Consulting Fees:AbbVie Company, Alexion Pharmaceuticals, Inc., Biogen Idec, Bristol Myers Squibb, EMD Serono, Inc., Genentech, Janssen Scientific Affairs, LLC, Novartis Pharmaceuticals Corporation, Sanofi, TG Therapeutics

Speakers Bureau: AbbVie Company, Alexion Pharmaceuticals, Inc., Biogen Idec, Bristol Myers Squibb, EMD Serono, Inc., Genentech, Janssen Scientific Affairs, LLC, Novartis Pharmaceuticals Corporation, Sanofi, TG Therapeutics

Contracted Research: EMD Serono, Inc., Genentech and Novartis Pharmaceuticals Corporation

Disclosure of Financial Relationships
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC and Catamount Medical Education require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC and Catamount Medical Education mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and Catamount Medical Education seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and Catamount Medical Education are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.

Our Policy On Privacy

The Consortium of Multiple Sclerosis Centers and Catamount Medical Education, LLC, respect your privacy. All personal information that is provided to Catamount Medical Education, LLC, is protected and will not be sold to a third party for commercial purposes. All personally identifiable information contained in the Catamount Medical Education, LLC, registration databases is treated as confidential and will be used only for the purposes stated in this policy, except where required by law. Catamount Medical Education, LLC, maintains user databases that contain mailing and user profile information as well as a record of the CME activities viewed and the post-test and evaluation results for CE credit. This information is provided to activity collaborators for the purposes of CE recordkeeping. By participating in this activity, you agree that Catamount Medical Education, LLC, has full permission to provide this information.

Catamount Medical Education, LLC, safeguards against the loss, misuse, or alteration of information that we have collected in this activity.

Disclosure of Unlabeled Use

CMSC and Catamount Medical Education require CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA-approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

For questions about this activity, please contact Catamount Medical Education at: [email protected].